Pharmacokinetics and Relative Bioavailability of 11634 Immediate Release Tablet in Healthy Male Volunteers

NCT02214927 | Completed Phase 1

• 1 other identifier: 1234.12
• Study Type: interventional
• Target: 24
• Locations: 0 countries
• Sites: N/A

Brief Summary

• Characterisation of the relative bioavailability of the IR-tablet vs. oral drinking solution (no primary endpoint in a statistical sense)
• Safety and tolerability of the IR-tablet formulation and solution
• PK profile of the single ascending doses of the IR-tablet formulation (including analysis of dose proportionality)

Conditions

Healthy

Outcome Measures

Primary Outcomes (7)

• Number of subjects with adverse events

  up to 10 days after drug administration

• Number of subjects with clinically significant findings in vital signs (blood pressure, pulse rate)

  up to 10 days after drug administration

• Number of subjects with clinically significant findings in ECG

  up to 10 days after drug administration

• Number of subjects with clinically significant findings in laboratory tests

  up to 10 days after drug administration

• Assessment of tolerability by investigator on a 4-point scale

  up to 10 days after drug administration

• AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

  up to 24 hours after drug administration

• Cmax (maximum measured concentration of the analyte in plasma)

  up to 24 hours after drug administration

Secondary Outcomes (17)

• tmax (time from dosing to maximum measured concentration)

  up to 24 hours after drug administration

• AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 up to the last quantifiable data point)

  up to 24 hours after drug administration

• λz (terminal rate constant in plasma)

  up to 24 hours after drug administration

• MRTpo (mean residence time of the analyte in the body after oral administration)

  up to 24 hours after drug administration

• CL/F (apparent clearance of the analyte in plasma after extravascular administration)

  up to 24 hours after drug administration

Study Arms (2)

BI 11634 single rising dose

EXPERIMENTAL

tablet

Drug: BI 11634 tablet

BI 11634 cross-over

EXPERIMENTAL

sequence: 1. tablet 2. drinking solution

Drug: BI 11634 tablet; Drug: BI 11634 drinking solution

Interventions

BI 11634 tablet DRUG

BI 11634 cross-over; BI 11634 single rising dose

BI 11634 drinking solution DRUG

BI 11634 cross-over

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy Caucasian males according to the following criteria, based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate), 12-lead ECG, clinical laboratory tests
• Age ≥18 and ≤50 years
• Haemoglobin within the normal ranges
• Body Mass Index (BMI) ≥18.5 and BMI ≤29.9 kg/m2
• Signed and dated written informed consent prior to admission to the study in accordance with Good clinical practice (GCP) and the local legislation

You may not qualify if:

• Relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
• Relevant surgery of gastrointestinal tract
• History of any bleeding disorder or acute and chronic blood coagulation defect, for the subject itself or any person of his family as far as known
• History of gastric ulcera and cholecystectomy
• Occult blood in faeces
• Relevant diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
• History of relevant orthostatic hypotension, fainting spells or blackouts
• Relevant chronic or acute infections
• History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
• Intake of drugs with a long half-life (\>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
• Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
• Use of acetylsalicylic acid or any other non-steroidal anti-inflammatory drugs (NSAID) within 2 weeks of study start until the end of study
• Participation in another trial with an investigational drug within two months prior to administration or during the trial
• Alcohol abuse (more than 40 g/day)
• Drug abuse

Sponsors & Collaborators

• Boehringer Ingelheim: lead

MeSH Terms

Interventions

N-(1-(5-chloro-1H-benzimidazol-2-yl)-2-methoxyethyl)-3-methyl-4-(3-oxo-4-morpholinyl)benzamide

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 12, 2014
• First Posted: August 13, 2014
• Study Start: May 1, 2007
• Primary Completion: July 1, 2007
• Last Updated: August 13, 2014

Record last verified: 2014-08